izpis_h1_title_alt

Overview of immune checkpoint inhibitors in gynecological cancer treatment
ID Pirš, Boštjan (Author), ID Škof, Erik (Author), ID Smrkolj, Vladimir (Author), ID Smrkolj, Špela (Author)

.pdfPDF - Presentation file, Download (731,71 KB)
MD5: 3A16559924EAAE54BC5F454D5EB80E1B
URLURL - Source URL, Visit https://www.mdpi.com/2072-6694/14/3/631 This link opens in a new window

Abstract
In the last ten years, clinical oncology has been revolutionized by the introduction of oncological immunotherapy, mainly in the form of immune checkpoint inhibitors (ICIs) that transformed the standard of care of several advanced solid malignancies. Using ICIs for advanced gynecological cancers has yielded good results, especially for endometrial cancer. In ovarian or cervical cancer, combining ICIs with other established agents has shown some promise. Concurrently with the clinical development of ICIs, biomarkers that predict responses to such therapy have been discovered and used in clinical trials. The translation of these biomarkers to clinical practice was somewhat hampered by lacking assay standardization and non-comprehensive reporting of biomarker status in trials often performed on a small number of gynecological cancer patients. We can expect increased use of ICIs combined with other agents in gynecological cancer in the near future. This will create a need for reliable response prediction tools, which we believe will be based on biomarker, clinical, and tumor characteristics. In this article, we review the basic biology of ICIs and response prediction biomarkers, as well as the latest clinical trials that focus on subgroup effectiveness based on biomarker status in gynecological cancer patients.

Language:English
Keywords:immune check-point inhibitor, biomarker, endometrial cancer, ovarian cancer, uterine cervical cancer, vulvar cancer, treatment response prediction
Work type:Article
Typology:1.02 - Review Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2022
Number of pages:24 str.
Numbering:Vol. 14, iss. 3, art. 631
PID:20.500.12556/RUL-137026 This link opens in a new window
UDC:618.1
ISSN on article:2072-6694
DOI:10.3390/cancers14030631 This link opens in a new window
COBISS.SI-ID:95979779 This link opens in a new window
Publication date in RUL:30.05.2022
Views:484
Downloads:97
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Cancers
Shortened title:Cancers
Publisher:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:01.02.2022

Secondary language

Language:Slovenian
Keywords:ginekologija, rak endometrija, biomarkerji, rak jajcevodov, rak materničnega vratu, zdravljenje

Projects

Funder:Other - Other funder or multiple funders
Funding programme:University Medical Centre Ljubljana
Project number:TP20210160

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back